Too much potential here for a buyout. why sell when you have everything in place to be the next independent successful biotech story. We know this is the case, AM,, Celldex and the biotech world know how well positioned this company is for success, so why sell out ? The price would be at a serious premium and it's unlikely anyone will pony up the big bucks it woudl take to get it done. The price is also going to be a moving target for the next several years up, up and away from any buyout offers. Drug companies looking for budget deal for pipeline expansion in the immunotherapy space missed this one completely. Think billions , not hundreds of miilions.